CD274 and neoplasm: Together, these data indicate that the in situ vaccine improves the activation of tumor-infiltrating DCs and tumoral infiltration of CD8+ T cells, increases CD8+/Treg number ratios, and upregulates PD-L1 expression of tumor cells.